Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Ltd has announced the appointment of Stephen Roche as a director, effective from June 20, 2025. The announcement indicates that Roche currently holds no relevant interests in securities, suggesting a fresh start in his role, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is involved in medical testing and diagnostics, catering to a wide range of healthcare needs.
Average Trading Volume: 922,127
Technical Sentiment Signal: Sell
Current Market Cap: A$538.1M
See more data about ACL stock on TipRanks’ Stock Analysis page.